Psoriasis is a T-cell-mediated disease characterized histologically by an inflammatory infiltrate in which CD4+ T cells predominate in the dermis and CD8+ T cells localize to the epidermis. 1, 2 These cells produce cytokines consistent with a T-helper (Th) type 1 profile, i.e. interferon (IFN)-c, interleukin (IL)-2 and IL-12. 3, 4 This pattern of T cell infiltration, combined with evidence of Vb restriction of T cells within the epidermis of psoriasis plaques implicating antigenspecific inflammation, [5] [6] [7] has led to the hypothesis that psoriasis is a T-cell-mediated, probably autoimmune, disease. 1 Other diseases with similar immunological characteristics include rheumatoid arthritis, 8 multiple sclerosis, 9 type 1 diabetes mellitus 10 and systemic lupus erythematosus (SLE). 11 It has been suggested that natural killer (NK) cells and natural killer-T (NK-T) cells may play an important role in the pathogenesis of these diseases, and numbers of circulating NK cells are significantly reduced in these conditions. dictated mainly by the opposing forces of activatory and inhibitory receptors. The main function of NK cells is to recognize and lyse virally infected cells and malignant cells which do not express major histocompatibility complex (MHC) class I alleles. 16, 17 Autologous cells (which express MHC class I alleles) are immune from cytolysis as they are recognized by NK inhibitory receptors. 16, 17 NK-T cells are lymphocytes that express NK receptors but, unlike NK cells, also express T-cell receptors such as CD3, T-cell receptor-a and b, and the Vb receptors. 17, 18 NK-T cells (like NK cells) may be cytotoxic and immunoregulatory but are capable of significantly more cytokine production than NK cells, including secretion of IL-4, IL-5, IL-10 and IFN-c. 18 Both of these cell types have been implicated in the pathogenesis of autoimmune disease. We have measured the numbers of NK and NK-T cells in the peripheral blood of patients with psoriasis.
Patients and methods
The study was approved by the Salford and Trafford Local Research Ethics Committee. Patients with chronic plaque psoriasis were enrolled into the study if they had not been on systemic therapy for at least 4 weeks prior to study entry and were using topical emollients only. Clinical severity of psoriasis was measured using the well-validated Psoriasis Area and Severity Index (PASI), 19 which scores psoriasis according to body surface area involved and degree of erythema, scaling and infiltration of plaques. The maximum score is 72 but values higher than 12 are recognized as denoting severe psoriasis.
Ten millilitres of venous blood was collected into heparin (10 U mL )1 ), diluted 1 : 1 in 0AE9 w ⁄ v NaCl, and peripheral blood mononuclear cells (PBMC) separated by density gradient centrifugation through Histopaque-1077 (Sigma-Aldrich, Cambridge, U.K.). PBMC were removed from the interface layer into Dulbecco's modified Eagle's medium (DMEM) with 5% fetal calf serum (FCS). Cells were washed twice prior to use and resuspended at 2 · 10 7 cells mL )1 in DMEM with 5%
FCS and 0AE1% azide. PBMC were labelled with a panel of antibodies ( Table 1 ). The appropriate isotype control was used for each antibody and the appropriate secondary antibody, if necessary (streptavidin-peridinin chlorophyll protein, mouse antirat light chain-phycoerythrin or rat antimouse IgG1-phycoerythrin). Antibodies (either alone or in combination) were added to 50 lL (10 6 PBMC) and incubated in the dark at 4°C for 45 min. If secondary flow fluorescent conjugates were required, cells were washed once in 1 mL medium prior to a second incubation. Labelled cells were finally washed once in 1 mL medium and resuspended in 1% paraformaldehyde in phosphate-buffered saline with 0AE1% azide. Flow cytometry was carried out on a FACscan (Becton Dickinson, Oxford, U.K.) gated on the lymphocyte population (Fig. 1a,b) .
Statistical analysis
Statistical differences between psoriasis patients and controls were assessed using the multivariate general linear model (SPSS ver. 7.5.1; SPSS Inc., Chicago, IL, U.S.A.). As the data were assumed to be nonparametric, correlations between clinical variables and laboratory data were assessed using Pearson's correlations and a two-tailed t-test was used to assess significance. Results are expressed as mean ± SD unless otherwise stated.
Results
Fourteen patients with chronic plaque psoriasis (eight men and six women; mean ± SD age 46 ± 13 years; duration of psoriasis 16AE1 ± 8AE2 years; PASI 23AE5 ± 10AE6) and 13 normal controls (eight men and five women; mean ± SD age 34 ± 9 years) entered the study. 
Cell populations
There were significantly fewer PBMC expressing the NK-cell activatory receptors CD16 (P < 0AE001) and CD56 (P < 0AE003; Fig. 2a ) and NK-cell inhibitory receptors CD94 (P < 0AE001) and CD158a (P < 0AE02) in psoriasis patients compared with healthy controls (Fig. 2b) . Furthermore, there were significantly fewer CD16+ CD56+ (P < 0AE001), CD16+ CD57+ (P ¼ 0AE01) and CD16+ CD56+ CD57+ (P ¼ 0AE01) PBMC in psoriasis subjects compared with controls (Fig. 2a) . Of note, there was no significant difference between the numbers of circulating T cells (CD3+), NK-T cells (CD3+ CD56+ CD57+), activated lymphocytes (CD69+) or CLA+ cells between psoriasis patients and controls (Fig. 2b) . 14) ; h, normal controls (n ¼ 13). *P < 0AE05; **P < 0AE005. Data are presented as mean ± SEM. CLA, cutaneous lymphocyte-associated antigen.
There were no significant correlations between the clinical severity of psoriasis, as assessed by PASI, and circulating levels of NK cells, NK-T cells and activated T cells (Fig. 3) .
Discussion
We have demonstrated that the number of circulating NK cells is reduced in the peripheral blood of psoriasis patients compared with normal controls. Interestingly, the circulating numbers of NK-T cells, T cells (CD3+), activated lymphocytes (CD69+) and CLA+ cells were no different between the two groups. Previous studies, using different methodologies, have suggested that NK-cell activity may be reduced in patients with psoriasis or psoriatic arthropathy. [20] [21] [22] Cells expressing NK-cell antigens are present in plaques of psoriasis and it is thought that these cells may play a key role in the pathogenesis of psoriasis. 23, 24 The number of NK cells has also been found to be decreased in the peripheral blood of a variety of established autoimmune diseases which share immunological characteristics with psoriasis. These include multiple sclerosis, 13 type 1 diabetes mellitus 14 and SLE 15 which, like psoriasis, are characterized by a predominant Th1 cytokine expression in the target tissue. 11, 13, 14 It has been proposed that NK cells play a regulatory role in autoimmunity in these conditions. 16, 17 They may act as a source of Th2 cytokines which, when reduced, allows an overabundance of Th1 cytokines and resultant autoimmune activity. 16, 17, 25 It has been shown in a mouse model of multiple sclerosis that NK cell depletion increases the susceptibility to experimental encephalomyelitis. 26 NK cells also appeared to inhibit CD4+ activity in a mouse model of colitis. 27 Perhaps the absence of CD4+ inhibition could be a potential trigger for psoriasis. 28 It has been suggested that susceptibility to NK cell depletion may be genetically determined. 29 Recently, alleles for psoriasis susceptibility have been described in the MHC class I chain-related gene A (MICA).
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NKG2D protein, expressed on NK cells, is a receptor for MICA, 31 so it would appear that some NK cell interactions may be genetically influenced in a way that may predispose to psoriasis. In short, there is circumstantial evidence that NK cell depletion may be associated with increased autoimmunity, and this would be compatible with our findings in psoriasis. Classically, NK cells are initiators and regulators of inflammation and can act without prior stimulation. 16, 17 Immune responses can be categorized as innate or adaptive. The innate response is early, nonspecific and involves NK cells among other cell types, including monocytes. T cells are recruited as a key component of the adaptive response. 16, 17 On this basis we believe that the reduction in the number of circulating NK cells in psoriasis is most likely to be a primary event. It is, of course, possible that the reduced number of circulating NK cells in psoriasis patients is secondary to active inflammation. When such inflammation resolves, the number of circulating NK cells may increase towards normal: we intend to assess NK cell numbers before and after therapy for psoriasis. Secondly, and perhaps theoretically, it is possible that the observed reduction in the number of circulating NK cells is a consequence of an increase in a lymphocyte subset that we did not analyse. We believe this scenario unlikely, as, if correct, we would expect this also to affect the numbers of other circulating cell populations, not just NK cells.
In summary, we have demonstrated that NK cells are depleted in the peripheral blood of patients with psoriasis, but with maintenance of normal levels of NK-T cells, T cells and activated T cells: an analogous finding to those in other Th1-mediated autoimmune diseases. Although the role that NK cells play in autoimmunity is unclear, there is circumstantial evidence that NK cell depletion may lead to a Th1 cytokine bias and autoimmunity. Further studies are needed to elucidate the relevance of NK cell activity in psoriasis. 
